SG/CALL/ELI LILLY & CO/1000/0.1/20.03.26

SG/CALL/ELI LILLY & CO/1000/0.1/20.03.26 Share Price

DE000SW8XGF2

Market Closed - Bid/Ask 18:52:52 15/05/2024 BST			After market 19:49:05
8.11 ^EUR	+10.04%		8.23	+1.48%

1 month

+2.14%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart SG/CALL/ELI LILLY & CO/1000/0.1/20.03.26

Latest news about ELI LILLY AND COMPANY

UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down	03:49pm	RE
Eli Lilly Ethics/Compliance Chief Alonzo Weems to Retire	01:43pm	DJ
Eli Lilly: Alonzo Weems to retire at the end of the year	01:40pm	CF
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer	01:01pm	PR

More news

Quotes 5-day view

Date	Price	Change
15/05/24	8.11	+10.04%
14/05/24	7.37	+1.24%
13/05/24	7.28	-2.02%
10/05/24	7.43	-5.59%
09/05/24	7.87	-2.96%

Real-time Boerse Frankfurt Warrants

Last update May 15, 2024 at 06:52 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	Société Générale
WKN	SW8XGF
ISIN	DE000SW8XGF2
Date issued	11/04/2024
Strike	1,000 $
Maturity	20/03/2026 (674 Days)
Parity	10 : 1
Emission price	8.14 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	8.67 €
Lowest since issue	6.39 €
Spread	0.1 €
Spread %	1.21%

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company